PDL BioPharma (PDLI) Says Partner, Orphan Therapeutics, Completes Enrollment of Phase III Study of Terlipressin
Tweet Send to a Friend
PDL BioPharma (Nasdaq: PDLI) announced that its partner, Orphan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
